Kerecis is developing the MariGen™ Omega3 Extra Cellular Matrix technology for use in products to treat chronic wounds and for abdominal wall reconstruction. Our patent pending fish skin derived material improves upon current human and porcine technologies through improved economics and clinical performance, reduced disease transfer risk and absence of cultural constraints on usage.
Kerecis was established as a medical device / biotech company in 2009 and completed its seed round late 2009. In 2012 the company closed its "A" round and is targetting the close of "B" round in late 2013.
The company is actively seeking future licensing and distribution partners, while focusing on product development, intellectual property protection and clinical tests. Ideal potential technology licensees will have the ability to accelerate regulatory approvals and the market launch of these proprietary devices or provide access to key markets outside of the US.